Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
A dad was diagnosed with four of the deadliest brain tumours after feeling 'tingles' in his left arm for a month - and died ...
Norwich comfortably saw off Stoke 4-2 at Carrow Road to record their first win in four matches and reignite their bid to ...
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
The school leaders taking unprecedented action to ensure a safe learning environment with amenities in good working order ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...
An arsonist with 'extremist views' and who once set fire to a Stoke-on-Trent Thornton's shop said he has 'no remorse' for ...